Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.

Cancer genetics - 1 Nov 2022

Llorin Hannah, Graf Madeline, Chun Nicolette, Ford James

Abstract excerpt

BACKGROUND: Recent changes in oncology practice guidelines indicate that mutations in cancer susceptibility genes identified on tumor genomic profiling (TGP) should prompt confirmatory germline testing. Our study aimed to determine the proportion of patients with TGP-identified mutations in moderate risk breast and ovarian cancer genes who previously would not have been considered for germline testing. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Genetic Predisposition to Disease
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Oncogenes

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 36116289
DOI: 10.1016/j.cancergen.2022.09.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.PMID 36116289Read ↗

Prevalence and Distribution of Unexpected Actionable Germline Pathogenic Variants Identified on Broad-Based Multigene Panel Testing Among Patients With Cancer.Semantic proximity Read ↗

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.Semantic proximity Read ↗

Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic SequencingSemantic proximity Read ↗

Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach.Semantic proximity Read ↗

Prevalence of Potentially Pathogenic Germline Variants Among Adult Patients in the Philippines With Solid Malignancies Who Underwent Tumor Genomic Profiling.Semantic proximity Read ↗

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsSemantic proximity Read ↗

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Semantic proximity Read ↗

Comprehensive Genomic Profiling in Metastatic Solid Tumors: High Actionability But Low Implementation in Real-World PracticeSemantic proximity Read ↗

The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.Semantic proximity Read ↗

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.Semantic proximity Read ↗

Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.Semantic proximity Read ↗

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.